Merck Expands Production Know-how to Deliver Full End-to-End Solution for Biopharma Industry

Merck, a leading science and technology company, has announced the expansion of its state-of-the-art single use current good manufacturing process (cGMP) facility with the addition of the Mobius 2000L single-use bioreactor.

With the new upstream suite at its Biodevelopment Center in France, Merck can now offer clients full process line cGMP manufacturing, comprised of Merck's own instrumentation and products.

"Our aim is to facilitate accelerated drug development and delivery via continued innovation and technical expertise by offering customers a complete end-to-end solution from clone to commercial production," said Udit Batra, CEO, Life Science at Merck. "Our unique offering gives customers the choice to transfer their production at any stage with the confidence that we will ensure the most efficient transition into commercial manufacturing - at either an existing facility or one we help them design."

With this increase in scale and scope, Merck can advance clients' recombinant products from cell line development through to late-stage clinical production. At the point of tech transfer out to a contract manufacturing organization or other facility, clients can also leverage Merck's Provantage^® End-to-End Services available worldwide to mitigate the risks traditionally associated with upscaling to commercial production.

Merck's Provantage^® End-to-End solution is a comprehensive suite of products and services that include process development, cGMP manufacturing, facility design, manufacturing equipment and consumables, process and equipment training, technology transfer and set-up for commercialization. The offering aims to minimize the risks for customers progressing from early clinical stages to commercial production helping to accelerate time to market and improve productivity and profitability.